FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362601815> ?p ?o ?g. }

• W4362601815 endingPage "e235439" @default.
• W4362601815 startingPage "e235439" @default.
• W4362601815 abstract "Importance Emergency department (ED)–initiated buprenorphine for the treatment of opioid use disorder (OUD) is underused. Objective To evaluate whether provision of ED-initiated buprenorphine with referral for OUD increased after implementation facilitation (IF), an educational and implementation strategy. Design, Setting, and Participants This multisite hybrid type 3 effectiveness-implementation nonrandomized trial compared grand rounds with IF, with pre-post 12-month baseline and IF evaluation periods, at 4 academic EDs. The study was conducted from April 1, 2017, to November 30, 2020. Participants were ED and community clinicians treating patients with OUD and observational cohorts of ED patients with untreated OUD. Data were analyzed from July 16, 2021, to July 14, 2022. Exposure A 60-minute in-person grand rounds was compared with IF, a multicomponent facilitation strategy that engaged local champions, developed protocols, and provided learning collaboratives and performance feedback. Main Outcomes and Measures The primary outcomes were the rate of patients in the observational cohorts who received ED-initiated buprenorphine with referral for OUD treatment (primary implementation outcome) and the rate of patients engaged in OUD treatment at 30 days after enrollment (effectiveness outcome). Additional implementation outcomes included the numbers of ED clinicians with an X-waiver to prescribe buprenorphine and ED visits with buprenorphine administered or prescribed and naloxone dispensed or prescribed. Results A total of 394 patients were enrolled during the baseline evaluation period and 362 patients were enrolled during the IF evaluation period across all sites, for a total of 756 patients (540 [71.4%] male; mean [SD] age, 39.3 [11.7] years), with 223 Black patients (29.5%) and 394 White patients (52.1%). The cohort included 420 patients (55.6%) who were unemployed, and 431 patients (57.0%) reported unstable housing. Two patients (0.5%) received ED-initiated buprenorphine during the baseline period, compared with 53 patients (14.6%) during the IF evaluation period ( P &amp;lt; .001). Forty patients (10.2%) were engaged with OUD treatment during the baseline period, compared with 59 patients (16.3%) during the IF evaluation period ( P = .01). Patients in the IF evaluation period who received ED-initiated buprenorphine were more likely to be in treatment at 30 days (19 of 53 patients [35.8%]) than those who did not 40 of 309 patients (12.9%; P &amp;lt; .001). Additionally, there were increases in the numbers of ED clinicians with an X-waiver (from 11 to 196 clinicians) and ED visits with provision of buprenorphine (from 259 to 1256 visits) and naloxone (from 535 to 1091 visits). Conclusions and Relevance In this multicenter effectiveness-implementation nonrandomized trial, rates of ED-initiated buprenorphine and engagement in OUD treatment were higher in the IF period, especially among patients who received ED-initiated buprenorphine. Trial Registration ClinicalTrials.gov Identifier: NCT03023930" @default.
• W4362601815 created "2023-04-06" @default.
• W4362601815 creator A5001033111 @default.
• W4362601815 creator A5005360853 @default.
• W4362601815 creator A5020449896 @default.
• W4362601815 creator A5025601376 @default.
• W4362601815 creator A5031386934 @default.
• W4362601815 creator A5038612293 @default.
• W4362601815 creator A5045061892 @default.
• W4362601815 creator A5045522401 @default.
• W4362601815 creator A5046216738 @default.
• W4362601815 creator A5048804811 @default.
• W4362601815 creator A5050035771 @default.
• W4362601815 creator A5053244935 @default.
• W4362601815 creator A5053520801 @default.
• W4362601815 creator A5054005119 @default.
• W4362601815 creator A5057961977 @default.
• W4362601815 creator A5059611577 @default.
• W4362601815 creator A5063652835 @default.
• W4362601815 creator A5073576560 @default.
• W4362601815 creator A5075327245 @default.
• W4362601815 creator A5075743971 @default.
• W4362601815 creator A5076117109 @default.
• W4362601815 creator A5076431340 @default.
• W4362601815 creator A5085763092 @default.
• W4362601815 creator A5090437860 @default.
• W4362601815 creator A5091506250 @default.
• W4362601815 date "2023-04-05" @default.
• W4362601815 modified "2023-10-17" @default.
• W4362601815 title "Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder" @default.
• W4362601815 cites W1985329916 @default.
• W4362601815 cites W2011592435 @default.
• W4362601815 cites W2071453859 @default.
• W4362601815 cites W2110409489 @default.
• W4362601815 cites W2119558113 @default.
• W4362601815 cites W2155170531 @default.
• W4362601815 cites W2158292788 @default.
• W4362601815 cites W2306592406 @default.
• W4362601815 cites W2792492758 @default.
• W4362601815 cites W2808907017 @default.
• W4362601815 cites W2917622711 @default.
• W4362601815 cites W2941362470 @default.
• W4362601815 cites W2947435448 @default.
• W4362601815 cites W2951609968 @default.
• W4362601815 cites W2965466510 @default.
• W4362601815 cites W3008834584 @default.
• W4362601815 cites W3013565570 @default.
• W4362601815 cites W3013787967 @default.
• W4362601815 cites W3022769978 @default.
• W4362601815 cites W3036796963 @default.
• W4362601815 cites W3085935546 @default.
• W4362601815 cites W3092700547 @default.
• W4362601815 cites W3126297842 @default.
• W4362601815 cites W3138071933 @default.
• W4362601815 cites W3169007053 @default.
• W4362601815 cites W3173223243 @default.
• W4362601815 cites W3176959550 @default.
• W4362601815 cites W3191866556 @default.
• W4362601815 cites W3198834800 @default.
• W4362601815 cites W3210052186 @default.
• W4362601815 cites W4200343406 @default.
• W4362601815 cites W4206903838 @default.
• W4362601815 cites W4247665917 @default.
• W4362601815 cites W4250746569 @default.
• W4362601815 cites W4254098136 @default.
• W4362601815 cites W4280537362 @default.
• W4362601815 cites W4283313519 @default.
• W4362601815 cites W4283577687 @default.
• W4362601815 cites W4283837407 @default.
• W4362601815 cites W4289841403 @default.
• W4362601815 cites W4292995121 @default.
• W4362601815 cites W4299689471 @default.
• W4362601815 doi "https://doi.org/10.1001/jamanetworkopen.2023.5439" @default.
• W4362601815 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37017967" @default.
• W4362601815 hasPublicationYear "2023" @default.
• W4362601815 type Work @default.
• W4362601815 citedByCount "5" @default.
• W4362601815 countsByYear W43626018152023 @default.
• W4362601815 crossrefType "journal-article" @default.
• W4362601815 hasAuthorship W4362601815A5001033111 @default.
• W4362601815 hasAuthorship W4362601815A5005360853 @default.
• W4362601815 hasAuthorship W4362601815A5020449896 @default.
• W4362601815 hasAuthorship W4362601815A5025601376 @default.
• W4362601815 hasAuthorship W4362601815A5031386934 @default.
• W4362601815 hasAuthorship W4362601815A5038612293 @default.
• W4362601815 hasAuthorship W4362601815A5045061892 @default.
• W4362601815 hasAuthorship W4362601815A5045522401 @default.
• W4362601815 hasAuthorship W4362601815A5046216738 @default.
• W4362601815 hasAuthorship W4362601815A5048804811 @default.
• W4362601815 hasAuthorship W4362601815A5050035771 @default.
• W4362601815 hasAuthorship W4362601815A5053244935 @default.
• W4362601815 hasAuthorship W4362601815A5053520801 @default.
• W4362601815 hasAuthorship W4362601815A5054005119 @default.
• W4362601815 hasAuthorship W4362601815A5057961977 @default.
• W4362601815 hasAuthorship W4362601815A5059611577 @default.
• W4362601815 hasAuthorship W4362601815A5063652835 @default.
• W4362601815 hasAuthorship W4362601815A5073576560 @default.
• W4362601815 hasAuthorship W4362601815A5075327245 @default.

• next